William J. Gradishar, MD, discusses the design and results of a study of intravenous versus subcutaneous pertuzumab and trastuzumab in patients with HER2-positive breast cancer.
William J. Gradishar, MD, professor of medicine (Hematology and Oncology), Betsy Bramsen Professor of Breast Oncology, and chief of hematology and oncology in the Department of Medicine at the Feinberg School of Medicine at Northwestern University, discusses the design and results of a study of intravenous (IV) versus subcutaneous pertuzumab (Perjeta) and trastuzumab (Herceptin) in patients with HER2-positive breast cancer.
In the phase 3 randomized FeDeriCa trial (NCT03493854), 500 patients with HER2-positive breast cancer received standard neoadjuvant chemotherapy plus IV pertuzumab and trastuzumab, or chemotherapy plus subcutaneous injection of pertuzumab, trastuzumab, and hyaluronidase-zzxf (Phesgo) every 3 weeks. Patients received 4 cycles of treatment before surgery and 14 cycles following surgery.
The subcutaneous injection demonstrated non-inferiority based on analysis of cycle 7 pertuzumab serum Ctrough concentration in each arm, reaching the primary end point of the lower bound of the geometric mean ratio being 0.8 or higher. The geometric mean ratio for the subcutaneous group versus the IV group was 1.22 (90% CI, 1.14-1.31). According to Gradishar, the pathological complete response (pCR) rate was 59.7% in the subcutaneous group and 59.5% in the IV group, making them roughly identical.
The toxicity profile also did not show differences between the groups, Gradishar says, concluding that the subcutaneous injection of pertuzumab and trastuzumab is equivalent to the IV form in tolerability and efficacy.
TRANSCRIPTION:
0:08 | So this was a neoadjuvant chemotherapy trial that basically looked at the use of a standard chemotherapy regimen preoperatively that was anthracycline or taxane-based with or without IV pertuzumab and trastuzumab, or the same chemotherapy option with subcutaneous pertuzumab and trastuzumab. And after surgery, patients were continued on the same HER2-directed therapy [that] they're given IV or subcutaneously. What was demonstrated in the trial is the pCR rate was exactly the same; whether you got IV or subcutaneous, it’s roughly around 60%. And the toxicity profile was no different between the 2 treatment arms.
Of course, if you look at things like, "How long did the patient require the infusion time?" In other words, the infusion time with the HER2-directed therapy was markedly less if you're getting a subcutaneous shot compared to an IV preparation of the same medication. So, on balance, it's equal efficacy, equal toxicity, and obviously shorter time in clinic to receive those particular medications.
Patient Preference Plays Limited Role in Selection of Therapy for Melanoma
May 17th 2024During a Case-Based Roundtable® event, Evan J. Lipson, MD, discussed with participants whether factors such as patient preference influence their choice of melanoma treatment in the second article of a 2-part series.
Read More
Discussing Non-Clinical Barriers to NGS Testing for NSCLC
May 15th 2024During a Case-Based Roundtable® event, Julia Rotow, MD, led a discussion on the non-clinical barriers that impact the use of using next-generation sequencing for patients with certain mutations of their non–small cell lung cancer in the first article of a 2-part series.
Read More
Lower-Dose Selinexor Data Lead to Patient Selection Questions in RRMM
May 14th 2024During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed which lines of therapy and at what doses would be appropriate to use selinexor in a patient with relapsed/refractory multiple myeloma in the second article of a 2-part series.
Read More
Experience and Sequencing Guide Third-Line DLBCL Therapy Selection
May 13th 2024During a Case-Based Roundtable® event, Matthew Ulrickson, MD, discussed experiences with loncastuximab and other targeted treatments in patients with diffuse large B-cell lymphoma with event participants in the first article of a 2-part series.
Read More